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Mouse and human livers contain innate immune leukocytes, NK cells, NKT cells, and macrophage-lineage Kupﬀer cells. Various
bacterial components, including Toll-like receptor (TLR) ligands and an NKT cell ligand (α-galactocylceramide), activate liver
Kupﬀer cells, which produce IL-1, IL-6, IL-12, and TNF. IL-12 activates hepatic NK cells and NKT cells to produce IFN-γ, which
further activates hepatic T cells, in turn activating phagocytosis and cytokine production by Kupﬀer cells in a positive feedback
loop. These immunological events are essentially evoked to protect the host from bacterial and viral infections; however, these
events also contribute to antitumor and antimetastatic immunity in the liver by activated liver NK cells and NKT cells. Bystander
CD8+CD122+ Tcells,andtumor-speciﬁcmemoryCD8+Tcells,arealsoinducedintheliverbyα-galactocylceramide.Furthermore,
adoptive transfer experiments have revealed that activated liver lymphocytes may migrate to other organs to inhibit tumor growth,
such as the lungs and kidneys. The immunological mechanism underlying the development of hepatocellular carcinoma in
cirrhotic livers in hepatitis C patients and liver innate immunity as a double-edged sword (hepatocyte injury/regeneration, septic
shock, autoimmune disease, etc.) are also discussed.
1.Introduction
The liver is the largest organ in vertebrates. Cumulative
evidence has indicated that not only the fetal liver but
also the adult liver is an important immune organ. The
livers in adult mice contain c-kit+ pluripotent hematopoietic
stem cells, which are located in the perisinusoidal Disse
spaces, and give rise to all lineages of leukocytes and red
blood cells [1–3]. c-kit hematopoietic stem cells have also
been identiﬁed in adult human livers [4]. When B cell-
and T cell-deﬁcient SCID mice were lethally irradiated and
received bone marrow cells as well as liver mononuclear
cells (MNCs) (but not splenocytes) from normal mice, the
SCID mice could survive, and the thymus, liver leukocytes,
splenocytes, and lymph nodes and bone marrow cells were
all reconstituted [1]. The administration of puriﬁed c-kit+
hematopoietic stem cells from either bone marrow or liver
MNCs into SCID mice also reconstituted leukocytes in all
organs [1]. In addition, liver Kupﬀe rc e l l sc o m p r i s e8 0 %
of the macrophage lineage cells in the whole body, and
most bacteria that enter the blood stream accumulate in the
liver and are killed by these Kupﬀer cells. In addition, other
innate immune lymphocytes, NK cells [5, 6], and T cells
withintermediatelevelsofTCR(TCRint cells)areabundantly
present in the liver [7], which are rarely seen in other organs
and peripheral blood.
Among mouse TCRint cells in the liver, 2/3 are
CD122 (IL-2 receptor β)+NK1.1+ NKT cells and 1/3 are
NK1.1−CD122+ T cells [3, 8–10]. The NK1.1+ NKT cells
are dependent on an MHC class-I like molecule, CD1d,
for their development, express an invariant Vα14Jα18/Vβ8
gene product for their T cell receptor (TCR), and have a
phenotype of CD4 or CD4−CD8−(double negative, DN)
(afterwards, NKT cells) [10, 11]. On the other hand,
NK1.1−CD122+ T cells are MHC class-I dependent for their
development, and predominantly (11%) express the Vα11
gene product for their TCR [10] and have a phenotype of
C D 8o rD N( 2 / 3a r eC D 8 + and 1/3 are DN) (afterwards,
CD8+CD122+ T cells). Since CD8+CD122+ T cells are also
present in athymic nude mice and increase age-dependently
in nude and normal mice, they may be of extrathymic origin.
Under physiological conditions, most MNCs (including
Kupﬀer cells, NK cells, TCRint cells) exist in the sinusoidal
space in the liver parenchyma. Kupﬀer cells tightly adhere2 Clinical and Developmental Immunology
Table 1: NKT cells are IL-12-induced antimetastatic eﬀectors.
Mouse strain/treatment Tumor Site of metastasis tested Number of tumor metastases
Control IL-12 treated % inhibition
BALB/c + IL-12 RL♂1 liver 216 ± 24 28 ± 2 87%∗
Colon 26 lung 125 ± 25 16 ± 10 87%∗
DBA/2 + lL-12 P815 liver 173 ± 12 10 ± 1 94%∗
C57BL/6 + IL-12 B16 lung 61 ± 16 5 ± 1 91%∗
EL4 liver 106 ± 22 17 ± 7 84%∗
C57BL/6 bg/bg + IL-12 EL4 liver 107 ± 17 16 ± 6 85%∗
C57BL/6 + IL-12 EL4 liver 96 ± 18 15 ± 4 84%∗
3LL lung 122 ± 26 25 ± 5 80%∗
C57BL/6 + αAGM1 Ab + IL-12 EL4 liver 102 ± 24 22 ± 5 78%∗
3LL lung 128 ± 32 33 ± 8 74%∗
C57BL/6 + αNK1.1 Ab + IL-12 EL4 liver 152 ± 26 130 ± 20 14%
3LL lung 204 ± 36 156 ± 28 24%
The mice were inoculated i.v. with syngeneic tumors. Data of tumor metastasis and % of inhibition are shown as mean ± SD from six to ten mice in each
group. ∗P <. 01. αAGM1 Ab: antiasialo GM1 antibody; αNK1.1 Ab: anti-NK1.1 antibody.
to sinusoidal endothelial cells, and NK/NKT cells are often
in contact with these Kupﬀer cells and may normally elicit
immunological functions to eliminate exogenous pathogens
present in liver sinusoids that enter from portal vein and
the systemic circulation. However, the localization of these
MNCs is altered under pathological conditions. In human
viral hepatitis or autoimmune hepatitis, a large number
of lymphocytes inﬁltrate into the portal areas (where the
portal vein, hepatic artery, and bile duct exist) and cause
periportal inﬂammation. The experimental hepatitis model
induced by α-galactosylceramide (α-GalCer, see Section 3)
in mice leads to pathological ﬁndings similar to human
viral hepatitis, such as piecemeal necrosis and apoptotic
Councilman bodies in and around the portal areas, although
MNCs also increased in sinusoids. These ﬁndings suggest
that the antigen activation process may be initiated in and
around portal areas.
NKT cells are mainly conﬁned in the liver, and the
proportion of NKT cells in liver MNCs remains constant
regardlessoftheageofthemouse,whereastheCD8+CD122+
T cells constantly increase in the liver, as well as in the
periphery, in an age-dependent manner [10]. In addition,
both TCRint cells display a potent IFN-γ producing capacity
andantitumorcytotoxicity[12].Notably,DNTcellswiththe
intermediate TCR expanded in the liver, spleen, and lymph
n o d e si na u t o i m m u n eM R L - lpr/lpr (lpr) mice may be an
abnormal counterpart to CD8+CD122+ T cells in the liver
of normal mice [7, 10]. Since the Fas (CD95) gene is muted
in lpr mice [13], it may accelerate the proliferation instead of
the apoptosis of activated CD8+CD122+ T cells in the liver,
and they may migrate into periphery after downregulation
of CD8 [10].
Bacteria and their components, lipopolysaccharide, pep-
tidoglycan-polysaccharide, and various toxins are physiolog-
ically brought from the intestine to the liver [14, 15]a n dm a y
stimulate these liver leukocytes and their antimicrobial and
antitumor immune function. In addition, the IL-6 produced
by Kupﬀer cells/hepatocytes stimulates hepatocytes to pro-
duce acute phase proteins (including CRP) and subsequent
complement production [16–18]. Therefore, the liver is
not only the organ for sugar, protein, and lipid/cholesterol
metabolism but also an immune organ. This review focuses
on the crucial role of the liver leukocytes in the antitumor
and antimetastatic immunity.
2. Inhibition of Hematogenous Tumor
Metastasesinthe LiverbyNKT Cells
StimulatedwithRecombinant
Interleukin-12(IL-12)
IL-12 was discovered in both mice and humans around 1990
as an NK cell stimulatory factor [19–21]. IL-12 was initially
thought to activate NK cells and cytotoxic CD8+Tc e l l st o
inhibit tumor metastasis. However, we found that the main
eﬀector cells that inhibit tumor metastasis of intravenously
(i.v.) injected tumors are NKT cells [22–25]. When liver
metastatic EL-4 cells (lymphoma), lung metastatic 3LL cells
(Louis lung carcinoma), and other tumors were injected
into B6 or other strains of mice via a tail vein, the main
antimetastatic eﬀectors in the liver, as well as in the lung,
were NKT cells (Table 1)[ 22–25]. However, NK cells were
not signiﬁcantly involved, because IL-12 exerted a potent
antimetastatic eﬀect in the liver and lung in NK-deﬁcient
beige (bg/bg) mice (Table 1)[ 23]. In addition, the depletion
of both NK cells and NKT cells by anti-NK1.1 Ab, but
not the depletion of NK cells alone by an asialo-GM1 Ab,
inhibited the IL-12-induced antimetastatic eﬀects in both
organs (Table 1)[ 25]. Furthermore, adoptive transfers of
various sorted lymphocyte subsets in liver MNCs from
IL-12-injected mice into tumor-inoculated mice conﬁrmed
that NKT cells, but not NK cells or CD8+T cells, are
antimetastatic eﬀectors in the liver, the lungs, and kidneys
[3, 24]. These results were further conﬁrmed in NKTClinical and Developmental Immunology 3
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Figure 1: Sequential activation of liver lymphocytes and antitumor
immunity by α-GlaCer.
cell-deﬁcient mice [26]. However, NK cells and CD8+ Tc e l l s
seem to be eﬀectors against subcutaneous tumor growth [3].
Although some researchers have claimed that NKT
cells disappear after IL-12 injection by activation-induced
apoptosis, and therefore could not be the antimetastatic
eﬀectors, we demonstrated that IL-12 merely downregulates
NK1.1 expression on NKT cells [27]. NKT cells in IL-12-
pretreated mice (24 hours before) were further activated by
the injection of a synthetic ligand, α-galactosylceramide (α-
GalCer), and were observed to produce much more IFN-γ,
as well as IL-4, and to acquire a more potent antitumor
cytotoxicity than those in mice without IL-12 pretreatment
[27]. It should be noted, however, that IL-12 pretreatment
increased TNF receptor and Fas-ligand (FasL) of NKT cells
and thereby augmented hepatotoxicity of NKT cells after
α-GalCer injection [27]. However, as described hereinafter,
such hepatotoxicity of α-GalCer-activated NKT cells can be
completelyinhibitedbyananti-TNF-Abwithoutattenuating
the antitumor immunity of the NK cells.
3. Inhibition of the Tumor Growth in the Liver
byα-GalCerandInductionofBystanderCD8+
CD122+ T Cells and Tumor-Speciﬁc Cytotoxic
CD8+ TC ell s
α-GalCer was initially identiﬁed and extracted from a
marine sponge, and thereafter synthesized by Kirin Brewery
Company [28], and was subsequently observed to strongly
inhibit the liver and lung growth of i.v. injected tumor
cells. α-GalCer was found to be a ligand of the invariant
Vα14Jα18/Vβ8 TCR of mouse NKT cells [29]. Therefore,
NKT cells were initially thought to be antitumor eﬀectors in
the liver and lung, but NK cells were also suggested to be
antitumor eﬀectors after α-GalCer injection. However, the
mice injected with α-GalCer were shown to have hepatic
injury [30, 31]. Thereafter, we demonstrated that the NK
cellsstimulatedwithIFN-γ producedbyα-GalCer-activated-
NKT cells are the main antitumor eﬀectors, whereas NKT
cells themselves are not antitumor eﬀectors, but they do
induce hepatotoxicity as a result of their increased FasL
expression [31, 32], in which lymphocyte inﬁltration and
apoptotic hepatocytes (Councilman bodies) were observed
in and around the portal areas. In addition, although NKT
cells were initially thought to disappear due to apoptosis,
and thus would not be able to further attack hepatocytes, it
wassubsequentlyfoundthattheNKTcellsmerelytransiently
downregulated both NK1.1 and TCR [33, 34], in a manner
similar to that observed after the injection of IL-12 [27].
These ﬁndings suggest that NKT cells downregulate their
receptors to inhibit their autoreactivity.
The antitumor function of liver NK cells and the liver
injury resulting from NKT cells induced by α-GalCer both
increase age-dependently [31, 32]. Interestingly, however,
when an anti-TNF Ab was injected simultaneously with α-
GalCer into aged mice after i.v. injection of EL-4 tumor
cells or intrasplenic injection of B16 tumor cells, the hepatic
injury was completely inhibited, without attenuating the
antitumor and antimetastatic activity of the liver NK cells
[35].
The α-GalCer-induced NK cells with antitumor activity
can kill not only NK-sensitive Yac-1 cells but also NK-
resistant B16 cells, EL-4 cells and Colon 26 cells, and can
inhibit the liver and lung metastasis of these NK-resistant
tumors [36, 37]. Therefore, such activated NK cells may
upregulate their killer activating molecules and/or downreg-
ulate their killer inhibitory molecules (e.g., CD94/NKG2A)
as described in Section 4. Furthermore, after the activation
of NK cells, bystander CD8+CD122+TCRint cells and tumor-
speciﬁc memory CD8+T cells were induced after α-GalCer
injection, thus allowing the mice to survive. Therefore, if
such memory is achieved against certain tumors (e.g., B16
cells), these mice can reject subcutaneously rechallenged
B16 cells but cannot reject other tumors (EL-4, Colon-26,
etc.) [38]. Following NK cell activation for 2 to 3 days
after α-GalCer injection, bystander CD8+CD122+cells with
NK cell-like antitumor activity without tumor-speciﬁcity
are increased at 3 to 7 days after α-GalCer injection, while
memory CD8+T cells, which are cytotoxic only against
certain tumors, are induced within two weeks (Figure 1).
Clinical trials using i.v. transfer of α-GalCer-pulsed DCs
or PBMCs stimulated with α-GalCer in vitro for patients
with advanced nonsmall cell lung cancer have been reported.
In one report, α-GalCer-pulsed PBMCs cultured with IL-
2 and GM-CSF were injected into patients four times, and
the patients with increased IFN-γ producing cells in the
PBMCs showed a longer survival (31.9 months, n = 17)
than the poor responder patients (9.7 months, n = 7) [39].
Although no severe adverse event related to the treatment
was observed, among several clinical trials, there was no case
of obvious tumor regression [39], and a further evaluation
of the survival beneﬁt of such immunotherapy is required. It
should also be noted that α-GalCer-reactive (speciﬁc) NKT
cells are rare in humans as described in Section 5.
4. Antitumor Immunity in the Liver Induced by
BacterialReagents
4.1. Lipopolysachharide (LPS). When mice were intraperi-
toneally (i.p.) or i.v. injected with a gram negative bacteria4 Clinical and Developmental Immunology
component, LPS, Kupﬀer cells were activated via toll-
like receptor- (TLR-) 4 [40] and produced IL-12, which
stimulated NK cells to produce IFN-γ and activated NKT
cells to acquire potent antitumor cytotoxicity [41]. As noted
in Section 1, exogenous IL-12 injection stimulates the IFN-γ
productionandantitumorcytotoxicityofNKTcells,whereas
NK cells are not main IFN-γ producers nor enhance their
antitumorcytotoxicity.However,inthecaseofLPSinjection,
NK cells are the essential IFN-γ producers, while NKT
cells are the main antitumor eﬀectors [3]. This relationship
between NK cells and NKT cells after LPS injection is
oppositetothatafterα-GalCerinjection(Table2).Therefore,
theIFN-γ-producingcellsandﬁnalantitumoreﬀectorsdiﬀer
based upon the stimulating reagent, whereasKupﬀer cells are
a constant provider of IL-12 [3].
The Kupﬀer cells activated by LPS also produce IL-
6 ,w h i c hs t i m u l a t e sh e p a t o c y t e st op r o d u c ea c u t ep h a s e
proteins (including CRP) and complement components [3].
CRPstimulatesKupﬀercellsviaFcγ receptorIIandenhances
their phagocytic activity [42]. Since a small amount of
LPS is considered to be continuously brought to the liver
from the intestines via portal vein, such an environment in
the liver induces a predominant presence of NK cells and
NKT cells in the liver sinusoids [3]. In fact, when mice are
maintained under the conventional condition, the number
of liver MNCs, including NK cells, NKT cells, and CD8+
CD122+ T cells, are increased up to 2-fold compared to
the numbers in mice maintained under SPF conditions,
especially in aged mice [43]. Although LPS injection into
mice triggers substantial antitumor immunity in the liver
against liver metastatic tumors (EL-4 cells, etc.), in contrast
to IL-12, LPS exerts antimetastatic eﬀects only when injected
before, but not after, tumor inoculation [41]. It is suggested
that LPS, but not IL-12, induces potent TNF production
from Kupﬀer cells/macrophages, which may induce adverse
eﬀects on the host defense, especially in tumor-inoculated
mice. In fact, TNF reportedly increased tumor metastasis to
the lungs [44].
4.2. Streptococcal Reagents. It has been well documented that
when a Streptococcus pyogenes derivative (OK432) is injected
to mice, the liver NK cells are increased and activated, and
they suppress tumor metastasis in the liver [45, 46]( T a b l e2).
TcellsandNKTcellsarenotlikelyinvolvedinthisantitumor
eﬀect, because depletion of NK cells alone by an antiasialo
GM1 Ab greatly diminished the antimetastatic eﬀect of
OK432. Since Streptococcus pyogenes is a gram positive bac-
teria that lacks LPS, either the teichoic acid, peptidoglycan-
polysaccharide, or DNA motifs of Streptococcus pyogenes may
stimulate Kupﬀer cells to produce IL-12 either through TLR-
2 (teichoic acid, peptidoglycan-polysaccharide) or TLR-9
(bacterial DNA).
4.3.BacteriaDNAMotifs(CpG-ODN). CpG-ODN(oligode-
oxynucleotides; GACGTT for mouse, GTCGTT for humans)
has been shown to activate innate immunity via the TLR-
9 expressed by macrophages [47–49]. This is an important
ﬁnding, because these DNA motifs are common in all
Table 2 :A n t i t u m o ro rh e p a t o t o x i ce ﬀectors in the liver.
Function Reagents
IL-12 α-GalCer LPS OK432 CpG
Antitumor eﬀectors NKT NK NKT NK NK
IFN-γ producers NKT NKT(NK) NK NK NK
Hepatotoxic eﬀectors NKT NKT NKT/NK ? NKT
bacteria, and every bacterial infection or invasion can
activate innate immunity in both humans and mice [49].
The diﬀerences in the frequency of unmethylated CpG
dinucleotides between bacterial and vertebrate DNA provide
a structural characteristic through which vertebrate immune
cells are activated and respond to a bacterial infection [47,
49]. The CpG-ODN thus mimics the stimulatory eﬀect of
the DNA of either gram-negative of gram-positive bacteria.
When CpG-ODN was injected into mice, the mouse Kupﬀer
cells produced IL-12 and TNF and activated NK cells, as well
as NKT cells in the liver (Figure 2).
Interestingly, IL-12-activated NK cells showed antitumor
cytotoxicity after CpG-ODN injection, whereas NKT cells
activated by TNF induced hepatocyte injury by expressing
FasL [50]. Although the antitumor cytotoxicity and IFN-γ
production of NK cells is attenuated with aging, the TNF
production from Kupﬀer cells and FasL expression and
hepatotoxicity of NKT cells are both augmented with aging
[50]. The antitumor activity of CpG-ODN-stimulated NK
cells may also be mediated by interferon-α [51], and the
IFN-α production was also decreased with age [50]. Again,
although the three bacterial reagents described above all
activate Kupﬀer cells to produce IL-12, it is not clear at
present why NKT cells are the main antitumor eﬀectors
induced by LPS, while NK cells are the main antitumor
eﬀectors induced by Streptococcal derivative and CpG-ODN
(Table 2). A further study is needed to address this issue.
It should be noted that although several bacteria and
their components have been suggested to be a natural
ligand of NKT cells, we feel that certain bacteria or their
components are not likely to be a ligand of NKT cells.
As described above, activation of NK/NKT cells by LPS or
CpG-ODN suggests that every gram positive or negative
bacterium can indirectly activate NKT cells. Furthermore,
major eﬀectors to ﬁght against bacteria are macrophages and
neutrophils.
5. Antitumor Cytotoxicityof
HumanCD56+TCells,CD16+CD56+NKCells,
andCD16−CD56++ NK cells
It has been proposed that human NKT cells could be T
cells bearing Vα24Jα18/Vβ11 gene products for their TCR,
because their TCR genes show sequence homology with the
mouse TCR Vα14Jα18/Vβ8 genes of NKT cells. In addition,
both such T cells in mice and humans are speciﬁcally
activated and proliferated by stimulation with α-GalCer.
However, we demonstrated that Vα24Jα18/Vβ11+ T cells are
very rare in human peripheral blood and liver MNCs [3, 52].Clinical and Developmental Immunology 5
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EvenintheliverMNCs,theyoccupylessthan0.5%ofTcells,
and we proposed that CD56+ T cells (mostly CD8+) are the
human counterpart of mouse NKT cells. The reasons are as
follows. (i) Human liver MNCs contain 25% CD56+ NK cells
and 20% CD56+ T cells, similar to mouse liver NK cells and
NKT cells [53]. (ii) The CD56+ T cells vigorously proliferate
and are activated after stimulation with IL-2 and IL-12 and
acquire potent antitumor cytotoxicity [53, 54]. (iii) CD56+
T cells have intermediate and pauciclonal TCRs similarly to
mouse NKT cells [55]. The NKT cells and NK cells therefore
likelyplayanimportantroleinpreventingtumorgrowthand
metastases in the human liver as well as in mouse liver.
Most human NK cells in peripheral blood mononu-
clear cells (PBMCs) are CD16+CD56+ NK cells (10∼15%
of PBMC), while a small number of CD16−CD56++ NK
cells, which express higher levels of CD56 than conven-
tional CD16+CD56+ NK cells, are present (approximate-
ly 1% in PBMCs and 10% of NK cells) [56–58]. Al-
though CD16−CD56++ NK cells are far less cytotoxic
than CD16+CD56+ NK cells in their resting state, when
puriﬁed and stimulated with IL-2, IL-12, and IL-15 for
several days, the CD16−CD56++ NK cells proliferate more
vigorously compared to CD16+CD56+ NK cells, and some
CD16−CD56++ NK cells acquire CD16 expression. These
CD16+ CD56++ NK cells produce a large amount of IFN-γ
and display strong antitumor cytotoxicities against not only
NK-sensitive K562 cells but also NK-resistant Raji cells [58–
61]. These cells are also induced by Streptococcal derivative
and heat-killed Streptococcus from PBMC or CD16−CD56++
NK cells [58]. Although most of these cells express NKG2A
(an NK-inhibitory receptor), they also express NKG2D
(an NK-activating receptor) and other natural cytotoxicity
receptors (NKp30, NKp44, and NKp46) and therefore can
kill NK-resistant tumors [58]. Interestingly, the majority of
NKcellsintheliver,colon,lymphnodes,uterus,andplacenta
are CD16−CD56+ NK cells [58, 62]. Therefore, these cells in
the human liver, when activated, may have the potential to
produce IFN-γ and kill various tumors. It can be speculated6 Clinical and Developmental Immunology
that NK cells in PBMCs are moving in the rapid blood ﬂow
in vessels and can therefore monitor pathogens and tumor
cells that invade the blood stream. They need to have the
NK activity to immediately attack virus-infected cells and
malignant cells and express CD16 (FcγRIII), presumably for
induction of antibody-dependent cell-mediated cytotoxicity
(ADCC) of infected cells, microbes, and tumors.
On the other hand, since NK cells in organs do not
usually encounter pathogens, they do not need to be in
an activated state. However, when once a pathogen/bacteria
invaded the organs, they need to be activated to reject
the pathogens. However, together with NKT cells, tissue
macrophages, and neutrophils, these cells sometimes induce
tissue damage and multiorgan dysfunction (MODS) as a
result of their autoreactivity, as is the case in septic shock.
Therefore, in order to reduce tissue damage, they are
thought to normally be in resting states. It should be noted
that mouse counterpart of human CD16−CD56++ NK cells
cannot be identiﬁed because mouse NK cells do not express
CD56. However, since activated NK cells induced by α-
GalCer, CpG-ODN, or a Streptococcal derivative can kill
NK-resistant tumors, similar NK cells may also exist in mice.
Whether these CD16−CD56++ NK cells and CD16+ CD56+
cells with NK activity are the same lineage cells or distinct
subsets needs further investigation.
6.CD16−CD56++ NK CellsinDiseases and
intheClinicalSetting
As described perviously, CD16−CD56++ NK cells and their
production of IFN-γ may play an important role in antitu-
mor immunity; however, the expansion of CD16−CD56++
NK cells has been observed in some diseases and in the
clinical setting. These cells are the ﬁrst lymphocytes to
appear in the PBMCs after bone marrow transplantation
[63]. These cells are also reportedly expanded in the PBMCs
of patients with systemic lupus [64], in the synovial ﬂuid
of patients with rheumatoid arthritis, and in patients with
autoimmune hepatitis [65]. In addition, as described above,
these cells were found to expand in vitro after stimulation
of PBMCs with a Streptococcus pyogenes reagent (OK-432)
[58], suggesting their involvement in bacterial infections. In
contrast, the number of CD56++ NK cells was decreased in
the PBMCs of patients with allergic rhinitis and/or asthma
[66], suggesting their role in Th1 but not Th2 immune
responses.
It has recently been reported that liver CD56+ NK
cells (presumably CD16− cells) were increased in the livers
of primary bilially cirrhosis (PBC) patients. These cells
are frequently seen in the portal area, within the biliary
epithelium, and around bile ducts [67]. NK cells from the
PBC livers stimulated with a combination of TLR-4 and
TLR-3 ligands (LPS and Poly I:C, resp.) in vitro exhibited a
higher cytotoxic activity against autologous primary human
biliary epithelial cells (cholangiocytes) than liver MNCs
from subjects with other liver diseases (viral hepatitis and
alcoholic liver disease), in which IFN-α-produced Kupﬀer
cells stimulated by the TLR-3 ligand may also be required
[67].TheseﬁndingssuggestanimportantroleforCD56+ NK
cells in PBC. Regarding NK and NKT cells in autoimmune
diseases, it should be noted here that NKT cells in mice and
humans reportedly inhibit autoimmune diseases (systemic
lupus, experimental encephaolomyelitis, Type I diabetes,
etc.). However, the role of NKT cells in autoimmune diseases
should be carefully evaluated, because NKT cell activation
by α-GalCer conversely accelerated the onset of lupus-like
symptoms, autoantibody production, and hepatotoxicity in
NZB/W mice [30, 68]. Further, the eﬀect of α-GalCer de-
pends on the mouse strains being examined [69].
Overall, these ﬁndings suggest that CD16−CD56++ NK
cells, together with conventional NK cells, NKT cells, and
Kupﬀer cells may play signiﬁcant roles in Th1 immune
responses against cancers and infections, in some autoim-
mune diseases, and also presumably in nonalcoholic steato-
hepatitis (NASH).
7. TheEffectsofAgingonAntitumorImmunity,
SepticShock,andMODS
The α-GalCer-induced antitumor immunity in the liver
(antitumor cytotoxicity) produced by NK cells and the
MODS induced by NKT cells unexpectedly both increases
with age [32]. In general, antitumor immunity in the liver
and other organs appears to decrease with aging, although
the proportions of CD57+ T cells (a human counterpart
of mouse CD8+CD122+ TCRint cells) and NK cells increase
with aging [54]. Consistently, CpG-ODN-induced antitu-
mor immunity and IFN-γ production from liver NK cells
decreasesage-dependently[50].ThesepticshockandMODS
in mice induced by CpG-ODN administration [70] also
worsened age-dependently, because macrophages/Kupﬀer
cells produce a large amount of TNF, and NKT cells
increase their FasL expression [50]. The septic shock induced
by IL-12 and low-dose LPS (16h apart) is called the
generalized Shwartzman reaction (GSR) and the GSR is
also aggravated with aging, because CD8+CD122+ cells with
IFN-γ producing capacity and the TNF production by
macrophages/Kupﬀer cells (ﬁnal eﬀectors for MODS) both
increase age-dependently [71]. Thus, liver innate immunity
can be a double-edged sword.
Using human PBMCs, an in vitro GSR-like phenomenon
can also be reproduced when the PBMCs are stimulated with
IL-12 and LPS (24h apart), because NK cells and CD57+
T cells with IFN-γ producing capacity increase with age,
and the TNF production from macrophages also increases
with age [72]. These results explain why septic shock after
abdominalsurgeryoccursmorefrequentlyinelderlypatients
[72]. Thus, innate immunity is a double-edged sword, and
aging attenuates the antitumor anti-microbial immunity but
aggravates tissue damage. Tissue damage or MODS can be
avoided by the administration of an anti-TNF-Ab [35, 50],
but the occurrence of any side eﬀects (bacterial infection,
especially tuberculosis) should be carefully monitored. In
this regard, synthetic CRP may be an eﬀective modulator
of innate immunity, which enhances the phagocytic actvity
of Kupﬀer cells and reduces their TNF production, withoutClinical and Developmental Immunology 7
attenuation of IFN-γ production from NK/NKT cells [42].
In fact, the administration of synthetic CRP improved the
survival of the mice from bacterial infections and GSR [42].
8. The Role of LiverNKT Cellsand
NKT CellsinHepatitisCCirrhosisPatients
andtheDevelopment ofHepatocellular
Carcinoma (HCC)
WepreviouslydemonstratedinhepatitisCpatientsthatNKT
cells (CD56+ T cells), and subsequently, CD56+ NK cells,
constantly decrease as hepatitis C progresses to cirrhosis, and
most of NKT cells and NK cells are lost in cirrhotic livers
[52].Consequently,whenliverMNCsobtainedfromsurgical
liver specimens of cirrhosis patients with HCC were cultured
with IL-2, IL-12, and IL-15, they showed decreased IFN-γ
production and antitumor cytotoxicity against both K562
cells and Raji cells, which was also the case against an HCC
cell line (HuH-7 cells) [52]. Liver NK cells can kill MHC
class-I (−) K562 cells, but not MHC class I (+) Raji cells,
because MHC class-I molecules inhibit NK cell cytotoxicity
by inhibitory signaling, while NKT cells eﬀectively kill Raji
cells, but not K562 cells. Interestingly, since HuH-7 cells
express low levels of MHC class-I, cytokine-activated NK
cells more eﬀectively kill HuH-7 cells than NKT cells [52].
These results suggest that the decrease of NK cells, as well
as NKT cells and their antitumor activities, is an important
immunological mechanism that may allow the development
of HCC in hepatitis C-associated cirrhotic livers. It was also
reported in mice that NKT cells were lost in CCL4-induced
cirrhotic livers [73]. These results suggest that maintenance
of NKT cells in the liver requires normal organization of liver
parenchyma. However, notably, if CD94/NKG2A (inhibitory
receptors) were blocked by an antibody, NK cells could
eﬀectively kill MHC class-I (−)t u m o r s[ 54]. In addition,
since most liver NK cells are CD16 negative and can be
activated by cytokines produced by Kupﬀer cells (IL-12, etc.)
and may express NKG2D and other activating molecules,
they can kill class-I (−) tumors. These ﬁndings suggest that
the relationship between NK cells (CD16+or−)/NKT cells and
tumor cells in the liver during antitumor immunity is more
complex than previously expected.
Although the functional impairment of NK cells and
NKT cells may also play an important role in the develop-
ment of HCC in hepatitis B patients, we could not ﬁnd any
decrease in CD56+ T cells and NK cells in the livers of HCC
patients with hepatitis B (our unpublished observation),
suggesting that the behavior of lymphocytes in hepatitis C
and hepatitis B may be diﬀerent. It is known that, although
most HCC cases develops in cirrhotic livers with hepatitis C,
HCC also develop in livers with hepatitis B patients without
apparent cirrhosis.
9. Possible Interactionsof TNF, NKT Cells, and
FasLwithHepatocytes
As described previously (Sections 3 and 4), although both α-
GalCer and CpG-ODN induce antitumor activity by hepatic
NK cells, they also activate NKT cells to induce hepatocyte
injury through the TNF/FasL/Fas pathway [31, 32, 50]. In
this regard, it has been unclear whether NKT cells express
FasL only to damage hepatocytes, or whether there is a
protective function. An important ﬁnding was that both α-
GalCer and CpG-ODN induce hepatocyte injury in aged
mice, but not in young mice [32, 50]. Furthermore, α-
GalCer-activated NKT cells accelerate hepatocyte and liver
regeneration after 70% partial hepatectomy (PHx) in mice,
which is also TNF/FasL-dependent, whereas NK cells are
inhibitory to liverregeneration [74].InFas-mutatedautoim-
mune lpr mice and NKT cell-deﬁcient CD1d−/− mice, and
in normal B6 mice depleted of TNF or FasL by neutralizing
Abs, there was no accelerated regeneration of the PHx liver
after α-GalCer injection [74] (Figure 2). Consistent with
theseresults,itwasreportedthatinjectionofexogenousTNF
or anti-Fas Ab into PHx mice accelerated the regeneration of
the PHx liver [75–77]. These ﬁndings suggest that NKT cells
may normally regulate the turnover of hepatocytes (newly
generated hepatocytes and old hepatocytes), the normal
lifespan of which is around 200 days [78]. Hepatocytes
nascent at the portal space gradually stream toward the
terminal hepatic vein, where they are probably eliminated by
apoptosis [78]. However, since most HCC shows reduced Fas
expression in both hepatitis B and C patients [79–81], HCC
maydevelopbyevadingsurveillanceofFasL-expressingNKT
cells.
10.TheRoleofNKCells,NKTCells,andK upffer
Cells inthe Development of LiverMetastasis
of Colon Cancers
Malignanttumors,especiallythoseofthecolonandstomach,
metastasize to the liver via the portal vein. Several exper-
imental studies in mice and rats have demonstrated that
NK cells are important antimetastatic eﬀectors in the liver.
NK cells are located in the liver sinusoids and adhere to
sinusoidal endothelial cells and Kupﬀer cells, which bind to
colon tumor cells injected from mesenteric veins, and kill
them. Since anti-asialoGM1 Ab treatment of mice, which
speciﬁcally depletes NK cells, greatly increased the number
of metastases of colon cancers, NK cells were considered
to be the main antimetastatic eﬀectors [46]. Interestingly,
when a OK432 was injected i.v. into mice, NK cells increased
in the liver, and the antimetastatic function of the liver
MNCs against colon cancers greatly increased [46]. This was
also the case for α-GalCer and liver NK cells. However, as
described above, the administration of either IL-12 or LPS
activates NKT cells and inhibits tumor metastasis in the
liver. Therefore, NK cells and NKT cells either independently
or cooperatively act as antitumor eﬀectors both in mice
and humans. However, the antitumor eﬀects of Kupﬀer
cells themselves are controversial. Although the cytokines
produced by Kupﬀer cells (IL-12, IFN-α) are indeed impor-
tant for the activation of NK cells and NKT cells and for
preventing tumor liver metastases, depletion of Kupﬀer cells
by gadolinium chloride or clodronate liposomes increased
the number of liver metastasis in some reports [82, 83] while8 Clinical and Developmental Immunology
it did not aﬀect the number of tumor metastases in the liver
in other reports [46]. In vitro experiments also showed that
Kupﬀe rc e l l sc a np h a g o c y t o s et u m o rc e l l sa n dc a nk i l lt h e m
[84], although another report contradicted this claim [85].
Our unpublished observations showed that NK cells and
NKT cells in the human liver tissues close to metastatic
colon tumors express less perforin than those in the liver
tissues distant from metastatic tumors, implying that tumor
metastasis starts to grow at the area where lymphocyte
activity is attenuated. Alternatively, tumors may produce
paracrine factors which may inhibit perforin production and
antitumor cytotoxicity of NK/NKT cells around tumors.
11. Concluding Remarks
The liver contains innate immune eﬀectors, Kupﬀer cells,
NK cells, NKT cells, and CD8+CD122+ cells, and these cells
cooperatively act not only against bacterial and viral infec-
tions but also against cancers. Many bacterial components
and toxins from the portal vein and systemic circulation
activate Kupﬀer cells to produce IL-12 and induce potent
antitumor activity by NK cells, NKT cells, and CD8+CD122+
cells via IFN-γ/perforin/granzyme pathway (Figure 2).
CD16−CD56++ NK cells in PBMC and presumably in the
liverofhumansmayalsoplayanimportantroleinantitumor
immunity, infections, and some autoimmune diseases. The
IFN-γ produced by these innate immune lymphocytes in the
liver in turn stimulates the phagocytic activity and cytokine
production of Kupﬀe rc e l l sv i aap o s i t i v ef e e d b a c kl o o p
(Figure 2). Liver NK cells, NKT cells, and CD8+CD122+
cells may also migrate to other organs to inhibit tumor
growth there. Decreased NKT cells and NK cells in cirrhotic
livers in hepatitis C patients may therefore allow for the
development of HCC. However, the TNF produced by
KupﬀercellsandTNF-activatedliverlymphocytes,NKTcells
andNKcells,mayberesponsibleforsepticshock,hepatocyte
injury/regeneration,cholangiocyteinjury,andMODSviathe
TNF/FasL/Fas pathway (Figure 2).
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